Madrigal Pharmaceuticals Reports Positive Two-Year Results for Rezdiffra in Phase 3 MAESTRO-NAFLD-1 Trial for MASH Cirrhosis
10/5 13:20
Madrigal Pharmaceuticals reported significant two-year trial results for Rezdiffra, showing improved liver stiffness and reduced portal hypertension risk....